Qiming readies to deploy $1.1B new China fund in the age of COVID-19
With largest fund yet, the firm will invest in biopharma, devices, diagnostics, services and healthcare IT
Now that it has closed its new $1.1 billion fund, Qiming will begin plotting its path through the economic downturn caused by COVID-19 by capitalizing on low valuations and fewer competing investors for assets.
Managing Partner Nisa Leung, who has led Qiming’s healthcare investments since 2006, told BioCentury the new fund is the biggest yet for the firm, which has more than $5 billion under management.
Nearly all of the largest LPs from